drugset / Trial / NCT00994123

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00994123

Phase 1/2 Completed 162 enrolled Merrimack Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).

Timeline

Start
2010-02
Primary completion
2014-11
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule Oral
Subject Seribantumab Monoclonal antibody Intravenous